Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2026 (Filing Date: August 6, 2026)
Principal Executive Office: Winzerlaer Str. 2, 07745 Jena, Germany
This filing serves to incorporate by reference the company's Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the three and six months ended June 30, 2026, as well as a press release dated August 6, 2026.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial data contained in the referenced exhibits (99.1 and 99.2). Consequently, the filing text does not provide a clear value for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Operating Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or results of operations compared to prior periods. Such analysis is contained within the incorporated Exhibit 99.2 (MD&A), which is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These elements are expected to be found in the incorporated Exhibit 99.2 (MD&A) and Exhibit 99.3 (Press Release), which are not provided in the source text.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2026.
- Examine Exhibit 99.2 for Management's Discussion and Analysis to understand operational results and liquidity trends.
- Read Exhibit 99.3 (Press Release dated August 6, 2026) for any material announcements or updates regarding clinical trials or partnerships.
- Verify the incorporation by reference into Registration Statements on Form S-8 (File Nos. 333-221656 and 333-240185).